A dry granulation process for cyclophosphamide fine granules
The dry granulation process solves the stability and safety issues of cyclophosphamide formulations, providing a fine cyclophosphamide formulation with uniform particle size and good flowability, reducing production costs and dust exposure risks, and making it suitable for large-scale production.
Patent Information
- Application Number
- CN202611316241.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-27
- Publication Date
- 2026-11-10
AI Technical Summary
Existing cyclophosphamide formulations suffer from problems such as cumbersome granulation processes, high energy consumption, increased impurities, large batch-to-batch variations, and high risk of dust exposure. In particular, wet granulation and direct mixing processes are difficult to meet stability and safety requirements.
The entire process employs a solvent-free dry granulation method, which involves water-cooled roller pressing, two-stage crushing and granulation, and fine powder recovery granulation. Combined with the mixing of inner and outer auxiliary materials, temperature and humidity are controlled to ensure uniform particle size, good flowability, and reduce impurity generation.
This invention achieves cyclophosphamide fine granules with uniform particle size, good flowability, low impurities, and good batch stability, reducing production costs and occupational exposure risks, and making it suitable for large-scale production.
Smart Images

Figure CN123059005A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of cyclophosphamide formulation preparation technology, and specifically to a dry granulation process for cyclophosphamide fine granules. Background Technology
[0002] Cyclophosphamide is a first-line oral antitumor drug used in clinical practice. This compound is extremely sensitive to water and heat. Traditional production processes and storage methods easily lead to the loss of its water of crystallization, resulting in rapid hydrolysis and oxidation of anhydrous cyclophosphamide. This causes a significant increase in formulation-related substances, shortens the drug's shelf life, and poses potential safety hazards for clinical use. Furthermore, this compound is cytotoxic, and dust exposure poses serious occupational health risks to operators.
[0003] Currently, the oral formulations of cyclophosphamide on the market are mainly tablets and capsules, involving wet granulation and direct mixing processes. There are currently no fine granule dosage forms. The conventional preparation methods for fine granules are mostly wet granulation, extrusion spheronization, fluidized bed granulation, dry granulation, and direct mixing processes. Among them, wet granulation, extrusion spheronization, and fluidized bed granulation require the addition of solvents such as alcohol and water during production. Long-term contact between the active pharmaceutical ingredient and the solvent can easily lead to decrystallization reactions and other risks. Subsequent high-temperature drying and coating processes further aggravate drug degradation, making it difficult to control the impurity level of the finished product and failing to meet long-term stability requirements. The process is complex, energy-intensive, and has a long production cycle, resulting in high industrial production costs. While direct mixing is solvent-free and requires no drying steps, it has significant drawbacks: it only produces loosely mixed powders without particle skeletons, leading to poor system stability. This makes it highly susceptible to fluctuations in particle size, bulk density, and moisture content between different batches of active pharmaceutical ingredients (APIs) and excipients, resulting in significant batch-to-batch mixing variations and persistent difficulties in achieving uniformity of content under low drug loading. Furthermore, material stratification during transport and weighing is prone to occur, making precise dosage control impossible. Additionally, the high dust emissions from the raw fine powder pose a risk of occupational exposure to highly toxic dust; and the poor powder flowability leads to significant fluctuations in dispensing volume during manual measuring and automated bagging production.
[0004] To address this, a dry granulation method for cyclophosphamide fine granules was designed, characterized by uniform particle size, good flowability, small batch-to-batch variation, and excellent stability. This method aims to overcome the aforementioned problems as a product development focus, resolve the control risks associated with dry granulation processes for preparing low-melting-point drugs, and invent a dry granulation method for cyclophosphamide fine granules. Summary of the Invention
[0005] In order to overcome the shortcomings of the existing technology, the present invention aims to provide a dry granulation process for cyclophosphamide fine granules, which is solvent-free throughout the process, temperature-controlled and water-locking, with uniform particle size, excellent flowability and content uniformity, extremely low impurity increment, small batch-to-batch quality fluctuation, and simple process with lower working time and energy consumption, enabling continuous large-scale production.
[0006] To achieve the above-mentioned objectives, the present invention is implemented through the following technical solution:
[0007] This invention provides a dry granulation process for cyclophosphamide fine granules, comprising the following steps:
[0008] (1) Mixing: After sieving, cyclophosphamide is mixed with inner layer filler and inner layer lubricant in a mixer;
[0009] (2) Water-cooled roll forming: The mixture is fed into a dry granulator with a feeding speed of 10-30 rpm / min, a roller speed of 5-20 rpm / min, a cylinder pressure of 0.15-0.25 MPa, a roller gap of 0.2-1.0 mm, and 0-15℃ cooling water is introduced into the rollers to control the temperature and press the sheet belt.
[0010] (3) Two-stage crushing and granulation: the belt is coarsely crushed through a 12mm sieve in the first stage and finely crushed through a 0.8mm sieve in the second stage. The granulation speed in the first stage is 150~300rpm / min, and the granulation speed in the second stage is 150~300rpm / min.
[0011] (4) Fine powder recovery and granulation;
[0012] (5) Mixing of outer layer auxiliary materials: After dry granulation, the granules and fine powder are mixed with the outer layer filler and the outer layer lubricant to obtain cyclophosphamide fine granules.
[0013] In some preferred embodiments, the cyclophosphamide passes through a 40-100 mesh sieve.
[0014] Preferably, the cyclophosphamide passes through a 60-mesh sieve.
[0015] In some preferred embodiments, the mixing conditions in step (1) are 5~20 rpm / min for 5~15 min.
[0016] In some preferred embodiments, in step (2), the feeding speed is 10-20 rpm / min, the pressure roller speed is 7-15 rpm / min, the cylinder pressure is 0.15-0.21 MPa, the roller gap is 0.2-0.8 mm, and the cooling water temperature is 2-10℃.
[0017] In some preferred embodiments, in step (2), the feeding speed is 12-18 rpm / min, the pressure roller speed is 10-12 rpm / min, the cylinder pressure is 0.15-0.20 MPa, the roller gap is 0.3-0.7 mm, and the cooling water temperature is 5-8℃.
[0018] In some preferred embodiments, the ambient humidity RH ≤ 65% in step (2).
[0019] Preferably, the ambient humidity in step (2) is 45%≤RH≤65%.
[0020] In some preferred embodiments, the primary granulation speed in step (3) is 200~300 rpm / min, and the secondary granulation speed is 200~300 rpm / min.
[0021] In some preferred embodiments, the fine powder recycling granulation includes: recycling and granulating fine powder below 80 mesh as needed, with 0 to 3 recycling cycles.
[0022] In some preferred embodiments, the mixing parameters in step (5) are 5~20 rpm / min and 5~15 min.
[0023] In some preferred embodiments, the bulk density of the cyclophosphamide granules obtained by the dry granulation process is 0.4~0.8 g / cm³. 3 All particles passed through an 850μm sieve. The proportion of particles that did not pass through a 500μm sieve was less than 10wt%, the proportion of particles that passed through a 250μm sieve was greater than 80wt%, and the proportion of particles that passed through a 75μm sieve was less than 20wt%.
[0024] The present invention has at least the following beneficial effects:
[0025] This invention provides a dry granulation process for cyclophosphamide fine granules, which does not introduce any solvents such as water or alcohol throughout the entire process. This completely avoids the problems of cyclophosphamide crystal water loss and drug degradation caused by the damp heat of wet processes and fluidized bed processes. By using water-cooled temperature control and matching granulation parameters, the growth of related substances in the finished product is effectively controlled, significantly improving the long-term storage stability of the formulation. The finished product yield is higher, and the batch-to-batch particle size and content differences are smaller, avoiding the defects of direct mixing processes that are easily affected by batch fluctuations of raw materials and excipients and fail to meet the content uniformity standards. The dust generation of the entire process is significantly reduced, which can greatly reduce the occupational exposure risk caused by cytotoxic drug dust. The production time is shortened, the equipment energy consumption is lower, the process parameter range is wide, and it is suitable for continuous and large-scale production of cyclophosphamide fine granules with different drug loadings. It has strong industrial controllability and broad prospects for clinical translation applications. Attached Figure Description
[0026] Figure 1 This is a flowchart of the overall dry granulation process for the cyclophosphamide fine granule agent of the present invention.
[0027] Figure 2 This is a 25× microscope image of the cyclophosphamide granules from Example 1 of the present invention. Detailed Implementation
[0028] The cyclophosphamide granule composition of the present invention will be described in detail below through examples. Obviously, the described examples are only a part of the examples of the present invention, and not all of them. All other examples obtained by those skilled in the art based on the examples of the present invention without inventive effort are within the scope of protection of the present invention. Unless otherwise specified, the materials and excipients in the examples are all commercially available.
[0029] The following are the formulations of cyclophosphamide granulators used in the dry granulation process of the examples and comparative examples.
[0030] The superflowable starch used in the raw materials of the embodiments and comparative examples of this invention is granular corn starch with good flowability, and it comes from the manufacturer and model Colorcon StarCap®.
[0031]
[0032] Example 1
[0033] This embodiment provides a dry granulation process for cyclophosphamide fine granules, specifically including the following steps:
[0034] (1) Mixing: Pass cyclophosphamide monohydrate through a 60-mesh sieve, and add superfluid starch, calcium hydrogen phosphate dihydrate, magnesium stearate and sieved cyclophosphamide monohydrate into the mixer in sequence. Set the mixer to 20 rpm / min and mix for 10 min.
[0035] (2) Water-cooled roll forming: The mixture obtained in step (1) is added to a dry granulator. The granulation parameters are as follows: feeding speed 15 rpm / min, roller speed 10 rpm / min, cylinder pressure 0.15 MPa, roller gap 0.4 mm, rollers are circulated with 5℃ cooling water for temperature control, and the pressing sheet belt is pressed. The ambient humidity is 50±5%RH.
[0036] (3) Two-stage crushing and granulation: the sheet is coarsely crushed through a 12mm sieve in the first stage and finely crushed through a 0.8mm sieve in the second stage. The granulation speed in the first stage is 200rpm / min and the granulation speed in the second stage is 300rpm / min. The granulation is done once and the fine powder is not recycled for granulation.
[0037] (4) Mixing of outer layer excipients: Add the granules and fine powder obtained in step (3) together with mannitol and magnesium stearate into a mixer, set the mixer speed to 20 rpm / min, and the mixing time to 10 min to obtain cyclophosphamide fine granules.
[0038] Example 2
[0039] The specific implementation method is the same as in Example 1, except that the cyclophosphamide monohydrate is passed through a 40-mesh sieve.
[0040] Example 3
[0041] The specific implementation method is the same as in Example 1, except that the cyclophosphamide monohydrate is passed through a 100-mesh sieve.
[0042] Example 4
[0043] The specific implementation method is the same as that in Example 1, except that in step (2), the feeding speed is 30 rpm / min, the pressure roller speed is 7 rpm / min, and the roller gap is 0.2 mm.
[0044] Example 5
[0045] The specific implementation method is the same as in Example 1, except that the cylinder pressure in step (2) is 0.25 MPa.
[0046] Example 6
[0047] The specific implementation method is the same as in Example 1, except that in step (2), the feeding speed is 10 rpm / min, the pressure roller speed is 20 rpm / min, and the roller gap is 1.0 mm.
[0048] Example 7
[0049] The specific implementation method is the same as in Example 1, except that the cylinder pressure in step (2) is 0.20 MPa and the roller gap is 0.5 mm.
[0050] Example 8
[0051] The specific implementation method is the same as in Example 1, except that the cooling water temperature in step (2) is 15°C.
[0052] Example 9
[0053] The specific implementation method is the same as in Example 1, except that the fine powder is recovered 3 times in step (3).
[0054] Example 10
[0055] The specific implementation method is the same as in Example 1, except that the fine powder is recovered once in step (3).
[0056] Example 11
[0057] The specific implementation method is the same as in Example 1, except that the first-stage granulation speed in step (3) is 150 rpm / min and the second-stage granulation speed is 200 rpm / min.
[0058] Example 12
[0059] The specific implementation method is the same as in Example 1, except that the mixing speed in step (1) is 10 rpm / min and the mixing time is 5 min.
[0060] Example 13.
[0061] The specific implementation method is the same as in Example 1, except that the mixing speed in step (1) is 20 rpm / min and the mixing time is 15 min.
[0062] Comparative Example 1
[0063] The specific implementation method of Comparative Example 1 is the same as that of Example 1, except that the feeding speed in step (2) is 35 rpm / min, the pressure roller speed is 4 rpm / min, and the cylinder pressure is 0.28 MPa.
[0064] Comparative Example 2
[0065] The specific implementation method of Comparative Example 2 is the same as that of Example 1, except that in step (2), the feeding speed is 8 rpm / min, the pressure roller speed is 25 rpm / min, the roller gap is 1.2 mm, and the cylinder pressure is 0.12 MPa.
[0066] Comparative Example 3
[0067] The specific implementation method of Comparative Example 3 is the same as that of Example 1, except that the cooling water temperature in step (2) is room temperature 25°C.
[0068] Comparative Example 4
[0069] The specific implementation method of Comparative Example 4 is the same as that of Example 1, except that the secondary granulation screen in step (3) is 1.0 mm.
[0070] Comparative Example 5
[0071] The specific implementation method of Comparative Example 5 is the same as that of Example 1, except that the secondary granulation screen in step (3) is 0.5mm.
[0072] Comparative Example 6
[0073] The specific implementation method of Comparative Example 6 is the same as that of Example 1, except that the ambient humidity in step (3) is 75%RH.
[0074] Performance testing
[0075] Test Example 1. Particle size, yield, and phenomena observed during preparation.
[0076] The particle size distribution (weight of particles larger than 80 mesh / total weight of granulated particles and fine powder after granulation) and yield (total weight of granulated particles and fine powder after granulation / total feed amount) and phenomena observed during the granulation process of Examples 1-13 and Comparative Examples 1-6 were compared, and the results are shown in the table below:
[0077] Table 1 Comparison of particle size, yield, and phenomena observed during preparation.
[0078]
[0079] The results in the table above show that Examples 1-13 and Comparative Examples 1-6 have higher yields, indicating that dry granulation has a high yield. Examples 1, 4, 5, 6, and 7 show that the feeding speed, pressure roller speed, cylinder pressure, and roller gap have a significant impact on the thickness, formability, particle size, and particle hardness of the flakes. Comparative Examples 1 and 2 show that when the feeding speed, pressure roller speed, cylinder pressure, and roller gap exceed the set range, either flakes will crack or the flakes will not form properly. Examples 12 and 13 show that when the mixing speed and time are too low, uneven mixing of the lubricant will occur. Comparative Examples 4 and 5 show that after replacing the screen with a larger screen, both the particle size and particle size increase, while after replacing the screen with a smaller screen, both the particle size and particle size decrease. Comparative Example 6 shows that when the ambient humidity is high, water in the air will accumulate at the rollers, causing the material to become slightly wet.
[0080] Test Example 2. Powder Flowability Test
[0081] The bulk density and tapped density were measured according to the test methods in General Chapter 0993 of Part IV of the Chinese Pharmacopoeia 2025. The compressibility and Hausner ratio were calculated based on the measured bulk density and tapped density results. The flowability of the powder was evaluated according to the flowability evaluation index based on compressibility and Hausner ratio in the "Guidelines for Powder Flowability" of the Chinese Pharmacopoeia (see Table 4). The specific results are shown in the table below.
[0082] Table 2. Liquidity assessment based on compressibility and Hausner ratio
[0083]
[0084] Table 3. Results of Powder Flowability Test
[0085]
[0086] As shown in Table 3, except for Comparative Example 5 which had poor flowability due to too much fine powder, the compressibility of the other examples and comparative examples was between 16% and 20%, and the Hausner ratio was between 1.21 and 1.25. According to the evaluation criteria in Table 2, the flowability was within the good range.
[0087] Test Example 3. Particle Size Distribution Test
[0088] Test method: Take the total mixed sample and sieve it on a vibrating screen equipped with sieves of different aperture sizes. The particle size distribution results are shown in the table below.
[0089] Table 4. Particle size distribution test results
[0090]
[0091] The results showed that the particle size distribution of Examples 1-13 all met the requirements of passing through an 850μm sieve, with less than 10wt% of particles not passing through a 500μm sieve, more than 80wt% of particles passing through a 250μm sieve, and less than 20wt% of particles passing through a 75μm sieve. Comparative Examples 1 and 4, due to their larger particle size, and Comparative Examples 2 and 5, due to their smaller particle size, did not meet the above requirements and would affect flowability and mixing uniformity.
[0092] Test Example 4. Mixing Uniformity Test
[0093] Referring to the "Technical Guidelines for the Study of Mixing Uniformity and Controlled Dosage Unit Uniformity of Oral Solid Dosage Forms of Chemical Drugs", the total mixed samples of each embodiment and comparative example were sampled and tested. The test results are shown in the table below.
[0094] Table 5. Results of Mixing Uniformity Test
[0095]
[0096] The results showed that, except for Comparative Example 4, which had uneven mixing due to its large particle size, the RSD of the mixing uniformity of the other comparative examples and examples was <5.0%, indicating that the powder was mixed relatively uniformly.
[0097] Test Example 5. Dissolution Test
[0098] Test method: Dissolution and release determination method (Chinese Pharmacopoeia 2025 Edition, Part IV, General Chapter 0931, Method II). Operate in the dark. Use 900 ml of water as the dissolution medium, rotate at 50 rpm, and operate according to the method. Take a sample after 15 minutes to test the dissolution rate. The results are shown in the table below.
[0099] Table 6. Dissolution test results
[0100]
[0101] The results showed that, except for Comparative Example 1, which had a slightly lower dissolution rate at 15 min, the dissolution rates of the examples and other comparative examples prepared in this invention were all ≥85% at 15 min in aqueous medium, and all could achieve rapid dissolution.
[0102] Test Example 6. Related Substances Test
[0103] The detection methods were based on the standards of the raw material supplier and the pharmacopoeias of various countries. Liquid chromatography was used for detection, with a focus on high-temperature degradation impurities (D) and total impurities. The results are shown in the table below.
[0104] Table 7. Results of related substances tests
[0105]
[0106] The results showed that the related substances in each embodiment prepared by the present invention could be controlled within a small range. However, the impurity D and total impurities in comparative examples 1, 3, and 6 were too large, indicating that deviations from the set parameter range (higher particle hardness, uncontrolled roller temperature, and higher ambient humidity) would affect the related substances in the product.
[0107] Test Example 5. Stability Test
[0108] Examples 1-13 and Comparative Examples 1-6 were packaged in the same way and placed under intermediate conditions (30°C, 65% RH). Samples were taken in March to test the changes in properties, content, and related substances. The results are shown in the table below.
[0109] Table 8. Stability Test Results (Intermediate Conditions)
[0110]
[0111]
[0112] As can be seen from Table 8, the stability of Examples 1-13 under intermediate conditions is significantly better than that of commercially available tablets; the stability of Comparative Examples 1, 3, and 6 is worse than that of Example 1, indicating that deviation from the set parameter range will affect the stability.
[0113] In summary, the dry granulation process for cyclophosphamide fine granules disclosed in this invention employs water-cooled roller pressing for temperature control and a low-humidity environment throughout the process, effectively inhibiting the degradation of the active pharmaceutical ingredient by moisture and heat. The resulting granules exhibit uniform particle size distribution, excellent powder flowability, and stable batch-to-batch content uniformity. This process avoids the impurity increase problems caused by solvent contact and high-temperature drying in traditional wet granulation, while improving finished product yield and reducing losses through graded granulation and fine powder recovery. The entire process parameters are stable and controllable, requiring no organic solvents, effectively ensuring the long-term storage quality of the product. It is suitable for large-scale industrial continuous production and possesses high practical value and clinical application prospects in the industrialization of oral fine granules for children.
[0114] Finally, it should be noted that the embodiments listed above are merely preferred embodiments of the present invention, intended to clearly illustrate the technological concept of the present invention, and should not be used to limit the scope of protection of the present invention. Any adjustments to process parameters, equivalent structural substitutions, and optimizations of technical solutions made based on the core technology of the present invention without departing from the technological concept of the present invention should be included within the scope of protection covered by the claims of the present invention.
Claims
1. A dry granulation process for cyclophosphamide fine granules, characterized in that, Includes the following steps: (1) Mixing: After sieving, cyclophosphamide is mixed with inner layer filler and inner layer lubricant in a mixer; (2) Water-cooled roll forming: The mixture is fed into a dry granulator with a feeding speed of 10-30 rpm / min, a roller speed of 5-20 rpm / min, a cylinder pressure of 0.15-0.25 MPa, a roller gap of 0.2-1.0 mm, and 0-15℃ cooling water is introduced into the rollers to control the temperature and press the sheet belt. (3) Two-stage crushing and granulation: the belt is coarsely crushed through a 12mm sieve in the first stage and finely crushed through a 0.8mm sieve in the second stage. The granulation speed in the first stage is 150~300rpm / min, and the granulation speed in the second stage is 150~300rpm / min. (4) Fine powder recovery and granulation; (5) Mixing of outer layer auxiliary materials: After dry granulation, the granules and fine powder are mixed with the outer layer filler and the outer layer lubricant to obtain cyclophosphamide fine granules.
2. The dry granulation process according to claim 1, characterized in that, The cyclophosphamide passed through a 40-100 mesh sieve.
3. The dry granulation process according to claim 1, characterized in that, The mixing conditions in step (1) are 5~20 rpm / min for 5~15 min.
4. The dry granulation process according to claim 1, characterized in that, In step (2), the feeding speed is 10-20 rpm / min, the pressure roller speed is 7-15 rpm / min, the cylinder pressure is 0.15-0.21 MPa, the roller gap is 0.2-0.8 mm, and the cooling water temperature is 2-10℃.
5. The dry granulation process according to claim 1, characterized in that, In step (2), the feeding speed is 12-18 rpm / min, the pressure roller speed is 10-12 rpm / min, the cylinder pressure is 0.15-0.20 MPa, the roller gap is 0.3-0.7 mm, and the cooling water temperature is 5-8℃.
6. The dry granulation process according to claim 1, characterized in that, In step (2), the ambient humidity RH ≤ 65%.
7. The dry granulation process according to claim 1, characterized in that, In step (3), the primary granulation speed is 200~300 rpm / min, and the secondary granulation speed is 200~300 rpm / min.
8. The dry granulation process according to claim 1, characterized in that, The fine powder recycling and granulation includes: recycling and granulating fine powder below 80 mesh as needed, with 0 to 3 recycling cycles.
9. The dry granulation process according to claim 1, characterized in that, The mixing parameters in step (5) are 5~20 rpm / min and 5~15 min.
10. The dry granulation process according to any one of claims 1-9, characterized in that, The bulk density of the cyclophosphamide fine granules obtained by the dry granulation process is 0.4~0.8 g / cm³. 3 All particles passed through an 850μm sieve. The proportion of particles that did not pass through a 500μm sieve was less than 10wt%, the proportion of particles that passed through a 250μm sieve was greater than 80wt%, and the proportion of particles that passed through a 75μm sieve was less than 20wt%.
